{
    "clinical_study": {
        "@rank": "100952", 
        "acronym": "TELECAST", 
        "arm_group": [
            {
                "arm_group_label": "250 mg telotristat etiprate", 
                "arm_group_type": "Experimental", 
                "description": "One telotristat etiprate (250 mg) tablet and one placebo tablet administered three times daily"
            }, 
            {
                "arm_group_label": "500 mg telotristat etiprate", 
                "arm_group_type": "Experimental", 
                "description": "Two telotristat etiprate (250 mg) tablets administered three times daily"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Two placebo tablets administered three times daily"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on\n      the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid\n      (5-HIAA) levels."
        }, 
        "brief_title": "Telotristat Etiprate for Carcinoid Syndrome Therapy", 
        "condition": "Carcinoid Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoid Tumor", 
                "Malignant Carcinoid Syndrome", 
                "Serotonin Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years of age\n\n          -  All patients of reproductive potential must agree to use an adequate method of\n             contraception during the study and for 12 weeks after the Follow-up visit.\n\n          -  Histopathologically-confirmed, well-differentiated metastatic neuroendocrine tumor\n\n          -  Documented history of carcinoid syndrome\n\n          -  Patient is able and willing to provide written informed consent prior to\n             participation\n\n        Exclusion Criteria:\n\n          -  Presence of diarrhea attributed to any condition other than carcinoid syndrome.\n\n          -  Presence of 12 or more watery bowel movements per day\n\n          -  Positive stool examination for enteric pathogens, pathogenic ova or parasites, of\n             Clostridium difficile at Screening\n\n          -  Karnofsky Performance Status \u2264 60%\n\n          -  Presence of any clinically significant laboratory, medical history, or physical\n             examination findings deemed unacceptable by the Investigator\n\n          -  A history of short bowel syndrome\n\n          -  History of constipation within 2 years of Screening\n\n          -  Life expectancy < 12 months from Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02063659", 
            "org_study_id": "LX1606.1-303-CS", 
            "secondary_id": "LX1606.303"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "250 mg telotristat etiprate", 
                    "500 mg telotristat etiprate"
                ], 
                "description": "Telotristat etiprate (250 mg) in tablet form.", 
                "intervention_name": "Telotristat etiprate tablets (250 mg)", 
                "intervention_type": "Drug", 
                "other_name": "LX1606"
            }, 
            {
                "arm_group_label": [
                    "250 mg telotristat etiprate", 
                    "Placebo"
                ], 
                "description": "Matching placebo in tablet form", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kogara", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2217"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Leonards", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2065"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Herston", 
                        "country": "Australia", 
                        "state": "Queensland", 
                        "zip": "4029"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bad Berka", 
                        "country": "Germany", 
                        "zip": "99437"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "13353"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Heidelberg", 
                        "country": "Germany", 
                        "zip": "69120"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Marburg", 
                        "country": "Germany", 
                        "zip": "35043"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Munchen", 
                        "country": "Germany", 
                        "zip": "81377"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08035"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Barcelona", 
                        "country": "Spain", 
                        "zip": "08907"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28040"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Basingstoke Hampshire", 
                        "country": "United Kingdom", 
                        "zip": "RG249NA"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Coventry", 
                        "country": "United Kingdom", 
                        "zip": "CV22DX"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE59RS"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom", 
                        "zip": "M204BX"
                    }, 
                    "name": "Lexicon Investigational Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Australia", 
                "Germany", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome", 
        "overall_contact": {
            "last_name": "Shanna Jackson, Clinical Trial Mgr", 
            "phone": "281-863-3484"
        }, 
        "overall_official": {
            "affiliation": "Lexicon Pharmaceuticals, Inc.", 
            "last_name": "Doug Fleming, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence of treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Percent change from baseline in 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA)", 
                "safety_issue": "No", 
                "time_frame": "Week 12"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02063659"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change from baseline in the number of daily bowel movements", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in stool consistency", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in the number of cutaneous flushing episodes", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change from baseline in abdominal pain", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "measure": "Change in the frequency of rescue short-acting, somatostatin analog used to treat carcinoid syndrome symptoms", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }
        ], 
        "source": "Lexicon Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Lexicon Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}